Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.

Rapid Review

Pharmacoeconomic Evaluation

Summary

The HSE has approved reimbursement following confidential price negotiations December 2016.